Desmoplasia-related pathway

Desmoplasia-related pathway refers to the complex biological process of forming a dense, fibrotic tumor microenvironment, characterized by the activation of cancer-associated fibroblasts (CAFs) and the excessive deposition of extracellular matrix (ECM) proteins like collagen and hyaluronan [1][2]. This phenomenon is particularly prominent in pancreatic ductal adenocarcinoma (PDAC), where the desmoplastic stroma can comprise up to 80% of the tumor mass [1]. The resulting dense tissue creates a physical barrier that increases interstitial fluid pressure and impairs the delivery of systemic chemotherapies and immune cell infiltration [3]. The pathway involves multiple signaling axes, including Transforming Growth Factor-beta (TGF-beta), Hedgehog (Hh), and Vitamin D Receptor (VDR) signaling, which coordinate the crosstalk between tumor cells and the surrounding stroma [2][4]. While desmoplasia was historically viewed as purely pro-tumorigenic, recent evidence suggests that certain stromal components may provide a protective restraint against tumor invasion, making therapeutic targeting challenging [7]. Current pharmacological approaches aim to either deplete specific ECM components, such as hyaluronan via PEGPH20, or inhibit stromal signaling through FAK or TGF-beta inhibitors [3][5][6]. Additionally, reprogramming CAFs into a quiescent state using VDR agonists like paricalcitol represents a promising strategy to modulate the stroma without complete depletion [4]. Understanding the dual nature of the desmoplastic response is critical for developing effective therapies that enhance drug delivery while maintaining stromal restraint [7].

Other names

Desmoplastic reactionTumor stromaFibrotic tumor microenvironmentCancer-associated stroma

Therapeutic strategies involve the enzymatic depletion of extracellular matrix components, pharmacological reprogramming of activated fibroblasts, or inhibition of stromal signaling pathways to improve drug delivery and immune infiltration [2][3][4].